Skip to main content
. Author manuscript; available in PMC: 2022 Oct 6.
Published in final edited form as: Lancet HIV. 2022 Jul 28;9(9):e607–e616. doi: 10.1016/S2352-3018(22)00166-7

Table 3:

Comparison of quantitative survey responses in intervention versus control groups

Intervention: mean scores
Control: mean scores
Difference in score changes: intervention vs control (95% CI) p value*
Baseline Year 1 Change (95% CI) Baseline Year 1 Change (95% CI)

How familiar are you with IPT? 3·72 4·73 +0·52 (0·03 to 1·0) 4·05 4·09 +0·05 (−0·46 to 0·55) +0·47 (0·44 to 0·80) 0·0034
How strong is the evidence that isoniazid prevents active tuberculosis in HIV-infected patients? 3·75 4·38 +0·63 (−0·1 to 1·36) 4·14 4·18 +0·05 (−0·63 to 0·72) +0·59 (0·06 to 1·12) 0.015
How difficult is it for providers in this district to add isoniazid to standard care for HIV-positive people in order to prevent tuberculosis?§ 2·38 2·23 −0·15 (−0·99 to 0·69) 2·52 2·15 −0·36 (−1·31 to 0·58) +0·21 (−0·26 to 0·69) 0·183
How hard is it to influence changes in practice among frontline providers around tuberculosis management?§ 2·78 2·42 −0·37 (−1·0 to 0·27) 2·68 2·45 −0·23 (−0·86 to 0·41) −0·14 (−0·62 to 0·35) 0·282

The left column shows the survey questions, which were scored on a Likert scale with a range of 1–5. Responses to 1 and 5 scores are listed in the footnotes. IPT=isoniazid preventive therapy.

*

One-sided p value.

1=no knowledge of IPT, 5=high knowledge of IPT.

1=very weak, 5=very strong.

§

1=very easy, 5=very difficult; declining score (negative change) indicates decreasing difficulty (ie, increasing ease) for these questions.